Trinity Biotech is executing a Comprehensive Transformation Plan with WHO approval for outsourced manufacturing and expects further Adjusted EBITDA improvement. The company's Premier Hb9210 HbA1c Analyser achieved the prestigious IFCC Gold Classification for 2026, making it the only HbA1c system worldwide to earn this certification. The company is advancing next-generation CGM+ continuous glucose monitoring with needle-free sensor technology.
Cyborg Score Rationale
Q3 2025 showed positive momentum with revenue of $14.3M (+32% vs Q2 2025) and Adjusted EBITDA improvement to $0.5M from -$2.1M in Q2. However, the company faces regulatory challenges, with non-compliance with Nasdaq minimum bid price requirement as of February 2026, and also failing to meet the minimum market value of publicly held shares requirement. Strategic product wins offset near-term listing pressures.
Top Insights
Received a 9 million-unit WHO-prequalified TrinScreen HIV rapid test order with fulfillment in Q4 2025 and Q1 2026.
Received full regulatory approval for upstream manufacturing of flagship Uni-Gold HIV rapid test under offshored and outsourced production model, the final major regulatory milestone for manufacturing transformation.
August 2025 breakthrough trial results on redesigned needle-free glucose sensor confirmed elimination of finger-stick calibration requirement, de-risking CGM+ commercialization pathway.
Secured $25 million Standby Equity Purchase Agreement with Yorkville to expand commercialization and advance innovation agenda including CGM+.
Named Competitors
Clinical Diagnostics — Global clinical diagnostic products
Diagnostic Products — In vitro diagnostic solutions